Findings from RAPTOR suggest 5-year biochemical recurrence may be a good indication of prostate cancer cure status. Biochemical recurrence within 5 years of treating prostate cancer with radiotherapy ...

The estimated 10-year cumulative incidence of PCSM was 1.2% for those who did not experience biochemical recurrence within 5 years of radiotherapy vs 29.0% among those who did. Biochemical recurrence ...

Fred Saad, CQ, MD, FRCS, FCAHS, discusses how combining therapies like androgen receptor–targeted agents, androgen deprivation therapy, and docetaxel can potentially improve outcomes for metastatic ...

"We think that radiation therapy is one of the best treatment options available for kidney cancer," says Nicholas Zaorsky, MD, MS. Stereotactic body radiotherapy (SBRT) may provide the best ...

Demogeot discusses his team's GETUG 14 findings regarding early administration of ADT plus high-dose radiotherapy for intermediate to high risk prostate cancer. The data from the phase 3 GETUG trial, ...

"The landscape of prostate cancer management has evolved significantly over the past 30 years, with [active surveillance], advances in imaging and genetics, and improvements in the treatment of ...

"When determining which code you should use, you must consider your Medicare carrier’s published rules and commercial payer processing policies," write Jonathan Rubenstein, MD, and Mark Painter. The ...

The panelist discusses how incorporating chemotherapy into combination treatments for metastatic prostate cancer presents challenges such as increased resource requirements, the need for ...

Zaorsky discusses his team's ASTRO 2024 abstract showing clear benefit of radiotherapy and ablation in reduced kidney effects in patients with RCC. Stereotactic body radiotherapy (SBRT), partial ...

Data from the PARTIQoL trial show no significant difference in progression-free survival, bowel function, and other patient quality-of-life measures between PBT and IMRT. Proton beam therapy (PBT) and ...

"Patient-reported satisfaction scores were high for both telehealth and inpatient visits for both new and established encounters," says Daniel Carson, MD, MS. In this video, Daniel Carson, MD, MS, ...

home / peer-exchange / advancements-and-insights-in-non-muscle-invasive-bladder-cancer-emerging-pd-1-pd-l1-inhibitors ...